In Cell this week: GWAS with immunophenotyping to examine genetic architecture of the immune system, hepatitis C virus sequesters miR-122 during infection, and more.
The findings also provide new clues about the virus' well-established association with hepatocellular carcinoma.
The new company will be focused entirely on hepatitis B, although officials previously said that Tekmira's other non-HBV RNAi programs would continue to advance.
The new assay expands a portfolio of viral load monitoring tests for the Cobas 6800 and 8800 systems.
The company provided updates for its hepatitis C and Alport syndrome candidates, which are both set to enter Phase II testing this year.
The company also recently paid $7 million for an exclusive option on an undisclosed RNAi technology and related intellectual property.
The data also point to viral load reductions regardless of disease genotype, extent of patient liver fibrosis, or failure with other treatments.
The company also disclosed that it intends to continue working on its non-HBV RNAi drugs that have entered human testing, but was less clear about earlier-stage ones.
The news marks a key milestone for Tekmira, which announced earlier this month that it would merge with OnCore Biopharma to become an HBV-focused drug developer.
The news marks the latest setback for the company, which came under fire late last year over disappointing clinical results on the drug.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.